

From: VANDENBERGHE Kurt (CAB-VON DER LEYEN)
Sent: lundi 31 janvier 2022 13:49
To: [REDACTED] (CAB-VON DER LEYEN)
Cc: PETKOVA Jivka (CAB-VON DER LEYEN); [REDACTED] (CAB-VON DER LEYEN)
Subject: VTCs with [REDACTED] and [REDACTED] - 26 November 2021

Dear [REDACTED]

Following up on your question on transparency.

I personally would be inclined to [REDACTED].

Hereunder a brief summary of each meeting, in case needed.

Best,
Kurt

On the EC side, participants in both meetings were: President, Seibert, Gallina, Delsaux, Flosdorff, Piot, Vandenberghe

VTC with [REDACTED].

[REDACTED] explained the company's views on the omicron variant, notably from a scientific perspective, the possible need for an adapted vaccine and the role of existing vaccines.

Other aspects on which views were exchanged related to international travel bans, the need for sequencing, the importance of isolating infection cases and the interplay with seasonal flu.

VTC with [REDACTED], [REDACTED] and [REDACTED]

The three gentlemen presented the emerging scientific evidence on the omicron variant and further ongoing analysis. In the light of the emerging evidence, the recommendation was made to treat Omicron 'as if an vaccine escape variant'.

Pfizer and BioNTech explained the steps to be taken and the timing involved in developing an adapted vaccine, if one was needed.

Pfizer mentioned the good clinical results obtained for the oral vaccine pill.